title: Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy.
abstract: Major bleeding complications in STEMI patients result in significant mortality, morbidity and healthcare cost. Identification of patients at increased risk of bleeding is therefore essential. New biomarkers might be of incremental value to identify patients at risk for bleeding after primary PCI. A total of 26 biomarkers were measured at enrolment and analyzed at a central core laboratory in 464 STEMI patients in the HORIZONS-AMI trial. We investigated the relationship between tertiles of biomarker and in hospital non-CABG major bleeding. In hospital non-CABG major bleeding occurred in 3.7% of patients (n = 17). Increasing levels of cystatin C and D-dimer at admission were associated with higher rates of in hospital major bleeding. After adjustment for a risk score for bleeding, the odds ratio for in hospital major bleeding was 3.13 for cystatin C > 2.04 mg/L (p = 0.046) and 3.28 for ESAM > 34 ng/mL (p = 0.037). In this exploratory analysis of the HORIZONS-AMI biomarker substudy, high cystatin C and ESAM levels were associated with a higher risk of major bleeding. Larger studies are warranted to confirm the prognostic value of cystatin C and ESAM for major bleeding in STEMI patients.
authors.affiliation: Academic Medical Center-University of Amsterdam, Amsterdam, Netherlands.
authors.forename: Wouter J
authors.initials: WJ
authors.lastname: Kikkert
authors.forename: Bimmer E
authors.initials: BE
authors.lastname: Claessen
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: Roxana
authors.initials: R
authors.lastname: Mehran
authors.forename: Bernhard
authors.initials: B
authors.lastname: Witzenbichler
authors.forename: Bruce R
authors.initials: BR
authors.lastname: Brodie
authors.forename: Jochen
authors.initials: J
authors.lastname: Wöhrle
authors.forename: Adam
authors.initials: A
authors.lastname: Witkowski
authors.forename: Giulio
authors.initials: G
authors.lastname: Guagliumi
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Zmudka
authors.forename: José P S
authors.initials: JP
authors.lastname: Henriques
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Elias A
authors.initials: EA
authors.lastname: Sanidas
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Chantziara
authors.forename: Ke
authors.initials: K
authors.lastname: Xu
authors.forename: George D
authors.initials: GD
authors.lastname: Dangas
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000097:blood* / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D011183:Postoperative Complications / Q000097:blood / Q000175:diagnosis; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D017239:Paclitaxel